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Abstract
Microcrystals associated with joint diseases, namely monosodium urate, calcium pyrophosphate and
basic calcium phosphate, can be considered as ‘danger signals’ to the innate immune system and pro-
voke inflammation through inflammasome-dependent as well as inflammasome-independent pathways.
Direct crystal membrane interactions can also lead to cell activation. The result is the generation of IL-1b
and other pro-inflammatory cytokines. The primacy of IL-1b in the case of gouty inflammation has been
demonstrated by the efficacy of IL-1 inhibitors in clinical studies. These findings may be relevant to other
diseases where crystal formation is found, such as OA and atherosclerosis.
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Introduction
Crystal arthritis is a topic that does not attract enough
attention within rheumatology, probably due to the erro-
neous notion that all is understood in terms of pathophysi-
ology. The first convincing demonstration of crystals in the
joint fluid of certain forms of arthritis by McCarty and
Hollander [1] led to the widespread use of polarizing
microscopy in rheumatology clinics as a diagnostic tech-
nique, but the performance of such a simple diagnostic
test is not always taught during medical training and crys-
tals are not searched for systematically when joint fluids
are examined. Recent advances have stimulated new
interest in the subject, as microcrystals can be considered
as endogenous ‘danger signals’ and are potent stimula-
tors of immune as well as non-immune cells. The best
known microcrystals include monosodium urate (MSU),
calcium pyrophosphate (CPP) and basic calcium phos-
phate (BCP). Rarer causes of crystal arthritis are oxalate
and cholesterol. Principally, crystal formation takes place
due to high local concentrations of the solutes, but as yet
poorly understood physico-chemical and biochemical
factors also play a part in either promoting or preventing
crystallization. Once formed, they elicit reactions from
leucocytes as well as tissues where they are deposited,
such as skin, cartilage and ligaments. Acute inflammation
is the hallmark of the acute tissue reaction to crystals,
but a major enigma in the field is why crystal deposits
are often asymptomatic. This observation suggests that
besides crystal formation, other factors are necessary in
order for inflammation to develop fully. Alternatively,
there may be natural counter-regulatory mechanisms
that dampen down crystal-induced inflammation.
Indeed, it has been recently found that increased produc-
tion of TGF-b1, IL-1ra, IL-10 and soluble TNF receptor I/II
(sTNFR-I/II) and up-regulation of the intracellular cytokine
negative regulators CIS and SOCS3 were associated
with spontaneous resolution of acute gout [2]. Currently
our understanding of these pathways is still very
rudimentary.
Hyperuricaemia is the underlying cause of MSU crystal
formation and deposition, and persistent hyperuricaemia
predisposes to clinical gout in an incremental fashion [3].
The epidemiology of gout and hyperuricaemia has been
reviewed recently and the importance of dietary factors as
well as associations with the metabolic syndrome high-
lighted [4]. Local factors that may influence crystallization
of urate include connective tissue components such as
hyaluronan [5] and previous injury or OA [6]. Crystal diag-
nosis by polarizing light microscopy remains the gold
standard for the diagnosis of gout, and joint aspiration
should be performed to ascertain the diagnosis whenever
possible. The formation of CPP and BCP crystals is
determined principally by local factors that influence
the concentrations of the principal substrates: Ca2+, PPi
and phosphate in connective tissues, such as cartilage
(leading to chondrocalcinosis) and around ligaments
and tendons (calcific periarthritis). Several mechanisms
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have been elucidated, including the function of cell
membrane transporters of PPi and membrane phosphat-
ases (reviewed in [7]). Both BCP and CPP crystals are
recognized causes of pseudogout, and their presence in
OA cartilage and SF suggests a pathogenic role for cal-
cium-containing crystals in the development and progres-
sion of OA [811].
MSU and BCP crystals are danger
signals that activate the NLRP3
inflammasome
Infectious agents and damaged cells release molecules
that are potent stimulators of cells in the immune
system, as they contain danger-associated molecular pat-
terns (DAMPs) that are capable of binding to innate
immune receptors. In the ‘Danger hypothesis’ proposed
by Matzinger [12], these signals are key to the initiation of
an immune response, primarily by interacting with cells of
the innate immune system, such as dendritic cells and
macrophages, which in turn primes the adaptive immune
system. The number of DAMPs is constantly increasing,
as endogenous cell components that fulfil the functions
described become recognized. In 2003, uric acid released
from damaged cells was found to be a powerful adjuvant,
and hence was considered to be a DAMP [13]. Recently it
was demonstrated that the adjuvant property of alum was
accounted for by urate released by dying cells and sub-
sequent crystallization of urate. Immunization of mice with
ovalbumin + alum induced an allergic Th2 cell response
that could be inhibited by uricase treatment and repro-
duced by sensitizing mice with ovalbumin + MSU [14]. It
is therefore likely that locally released urate from dying
cells will crystallize and rapidly phagocytosed, initiating
inflammation pathways (Fig. 1).
A property common to many DAMPs is the capacity to
activate dendritic cells and macrophages to secrete
pro-inflammatory cytokines such as IL-1b. The production
of IL-1b is tightly controlled on several levels as it is a
potent cytokine that is active in picomolar concentrations.
The post-translational regulation involves the cleavage of
the inactive 35-kDa IL-1b precursor (pro-IL-1b) into the
active 17-kDa IL-1b. This process requires assembly of
FIG. 1 Mechanisms of crystals-induced inflammation. (1) Crystals eventually interact with membrane via Toll-like
receptor 2 (TLR2) and/or TLR4 or other receptors of the innate immune system. Upon phagocytosis, crystals induce
K+ efflux via ATP binding to P2X7R, ROS generation and lysosomal damage (probably via cathepsin B release). These
events lead to NLRP3 inflammasome activation. The resulting autocatalytic activation of caspase-1 then induces
pro-IL1b cleavage into biologically active IL-1b. (2) Alternatively, crystals can directly bind to the membrane, in a
receptor-independent manner, leading to Syk kinase activation, which in neutrophils is mediated by PKC. It is not known
at the moment what mediators are released upon Syk activation by MSU, apart from prostaglandin E2 (PGE2), neutrophils
and dendritic cells. Although pathway 2 (Syk kinase activation) is independent of pathway 1 (inflammasome activation),
lysosomal damage may be a common step for both pathways. Finally, there is no evidence yet for BCP crystal binding
and Syk activation.
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the cytoplasmic multiprotein complex, termed the inflam-
masome, responsible for the conversion of the zymogen
procaspase-1 into the active caspase-1 that mediates
IL-1b and IL-18 maturation [15]. As pro-IL-1b cleavage is
immediately followed by the release of the mature cyto-
kine, processing and secretion are coupled. Four major
inflammasome complexes activating caspase-1 have
been described to date: NLRP1, NLRP3, IPAF and AIM2
inflammasomes, among which NLRP3 is best studied [16].
The NLRP3 inflammasome is composed of NLRP3 pro-
tein, an adapter ASC protein as well as the inflammatory
caspase-1. The ASC adapter contains a pyrin domain
(PYD) that mediates interaction with a homologous
domain on NLRP, as well as a CARD domain that interacts
with caspase-1. A large number of stimuli have
been described to activate the NLRP3 inflammasome.
These can be from bacterial origin (such as the
pathogen-associated molecular patterns muramyl dipep-
tide, bacterial RNA or double-stranded RNA) or DAMPs.
The list of DAMPs triggering NRLP3 activation is currently
ever expanding, and includes different crystal structures
such as alum, haemozoin, silica and cholesterol crystals,
as well as crystals found in microcrystalline arthritis such
as MSU, CPP [17] and BCP crystals [18]. The diversity of
molecular structures represented by these compounds
makes it unlikely that they all interact directly with the
NLRP3 inflammasome.
The molecular mechanisms underlying processing and
secretion of active IL-1b have been studied mainly
in vitro in macrophages (Fig. 1). As expected, macro-
phages deficient for components of the NLRP3 inflam-
masome were unable to secrete active IL-1b following
stimulation with MSU, CPP and BCP crystals [17, 18].
These findings raise questions about the steps that con-
nect cellular contact of crystals and cytoplasmic inflam-
masome activation, processes that are still not
completely understood. These steps may involve general
mechanisms shared by other inflammasome activators,
such as (i) the phagocytosis of crystals; (ii) K+ efflux that
is regulated by K+ channels like P2X7R; (iii) sensing of
reactive oxygen species (ROS) that are released during
cell stress; and (iv) destabilization of the lysosomal mem-
brane and activation of the lysosomal protease cathepsin
B (see review in [19]). For both MSU and BCP crystals,
secretion of active IL-1b by macrophages was blocked
by cytochalasin-D, a phagocytosis inhibitor. In addition,
ROS formation and K+ efflux are also linked to MSU and
BCP crystal-induced IL-b secretion, as secretion was
completely inhibited by ROS inhibitors and by higher
extracellular concentrations of K+. However, controver-
sial results were obtained about the role of P2X7R.
MSU elicited a P2X7R-dependent IL-1b secretion in pri-
mary human monocytes [20] and murine macrophages
(N. Busso et al., unpublished results), in contrast with a
previous observation that blocking P2X7R pharmaco-
logically did not affect the MSU-induced release of
IL-1b by monocytic THP1 cells [17]. This discrepancy
may depend on the different cells analysed and the
stimulation protocol used.
MSU and BCP interaction with the cell
membrane and Syk kinase signalling
What are the first steps in the interaction between crystals
and cells? Phagocytosis was shown to be essential for
the activation of neutrophils [21] and macrophages [22],
and in the case of macrophages, TLRs may play a role.
An interaction of MSU crystals with TLR2 and TLR4
has been demonstrated, but the absolute need for TLRs
in MSU crystal-induced inflammation is controversial.
On the one hand, the presence of TLR2 and TLR4 exa-
cerbated MSU crystal-induced IL-1b production and PMN
recruitment in the murine air pouch model, but another
group found that none of the known TLRs were indispens-
able in the murine peritonitis model [22, 23]. We found that
both TLR2 and TLR4 were implicated in MSU and
octacalcium phosphate (OCP) crystal-induced IL-1b pro-
duction by monocytic THP1 cells, after the cells had been
primed with CpG or with TNF-a (N. Busso, unpublished
results).
A second mechanism is the direct activation of cell
membrane signalling cascades. A specific interaction of
MSU crystals with dendritic cells has been demonstrated
by atomic force microscopy to occur [24]. This interaction
appears to involve membrane cholesterol, actin polymer-
ization and activation of the tyrosine kinase Syk that might
mediate either internalization of the crystal or a cellular
response to the binding of the crystal (Fig. 1). Syk expres-
sion and its signalling mechanisms are mainly found in
haematopoietic cells, so other cell types that express
Syk could bind avidly to MSU crystals and respond to
them. Indeed, it was shown that intracellular signalling
events initiated by the physical interaction between MSU
crystals and neutrophils depended on the activation of
Syk kinase [25, 26]. However, there is still no evidence
for direct binding of MSU crystals to macrophage cell
membranes and for Syk signalling that could contribute
to the activation of the inflammasome by these crystals.
Finally, there are no reports to date of direct interactions
between BCP crystals and cell membranes and Syk
activation.
Role of the NLRP3 inflammasome in in
vivo models of crystal-induced joint
inflammation
The effects of MSU crystals have been studied in vivo
using three different modes of administration (subcuta-
neously, intraperitoneally or IA). When MSU crystals
were applied subcutaneously (air pouches) or intraperito-
neally, NLRP3, ASC or caspase-1 deficiency led to dimin-
ished influx of inflammatory cells in the particular cavity
[27, 28].
However, several researchers were unable to reproduce
the findings that NLRP3 deficiency resulted in a significant
reduction of cell influx after intraperitoneal administration
of MSU crystals [29]. Similar results were obtained with
two different NLRP3 knockout (KO) strains that showed a
lack of effect of NLRP3, suggesting that the genetic
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background of the various NLRP3 KO mouse strains used
is not the reason for these findings.
It has to be stressed that MSU crystals injected intra-
peritoneally in mice lacking functional caspase-1 activity
only led to a moderate reduction (50%) of cell influx in the
peritoneal cavity, indicating that caspase-1-independent
mechanisms can also mediate the inflammatory reaction
[17, 30]. Since during an acute attack of gout, the main
cell type present in the synovial cavity is the neutrophil,
it is likely that serine proteases originating from neutro-
phils (such as cathepsin G, elastase and, in particular,
proteinase 3) process pro-IL-1b to bioactive IL-1b in a
caspase-1-independent manner [31].
A novel model of murine gouty arthritis induced by IA
injection of MSU crystals in combination with long-chain
free fatty acids has been recently described, recapitulat-
ing some of the clinical features of gouty arthritis [32].
In this model, NLRP3 was found not to be involved in initi-
ating acute joint inflammation. However, ASC and
caspase-1 both contributed to acute inflammation, as the
influx of neutrophils, as well as local IL-1b production, were
strongly decreased in ASC and caspase-1-deficient mice.
Mice peritonitis induced by intraperitoneal injection of
OCP crystals was not prevented in NLRP3, ASC or
caspase-1 KO mice, whereas IL-1b blockade (with IL-1b
monoclonal antibody or IL-1Ra) was effective [33]. In this
latter model, OCP crystals induced neutrophil necrosis
with subsequent release of pro-IL-1b from intracellular
stores. Pro-IL-1b can then be processed extracellular,
possibly by neutrophilic proteases such as PR3, without
NLRP3 inflammasome involvement. Recently Flavell and
colleagues [34] reported on the role of the NLRP3 inflam-
masome in an animal model of OA, based on progressive
ankylosis and hydroxyapatite crystal formation in the
ANK-deficient mouse, suggesting that in OA, inflamma-
some-mediated pathways may play a role.
What have the in vitro and in vivo studies on crystals
taught us? Essentially that one has to be cautious to
extrapolate in vitro findings (in which MSU and BCP
effects are totally NLRP3 inflammasome dependent) to
the in vivo situation (in which MSU and BCP effects are
partially or totally NLRP3 inflammasome independent).
These differences are likely to be due to the different mix-
tures of cell types activated in vivo, as well as the involve-
ment of other pathways of inflammation besides the
release of IL-1b.
Other crystals and particles
Besides MSU, CPP and BCP crystals, cholesterol crystals
have also been shown to trigger the inflammasome to
promote IL-1b release from monocyte/macrophages. In
an in vitro model of atherosclerosis, it has been demon-
strated that mice with myeloid cells that carry deletions of
ASC, NLRP3 or IL-1a/b were protected from severe
atherosclerosis when fed a high-fat diet [35]. These find-
ings suggest that biological crystals are generally pro-
inflammatory through their interactions with the NLRP3
inflammasome complex, and that biological crystals can
have effects that are not limited only to rheumatological
conditions.
Another microparticle that is relevant to the current dis-
cussion is that released from prosthetic implants, such as
silicone and metallic prosthesis, as they can induce asep-
tic inflammation that in turn is associated with prosthesis
loosening. The NLRP3 inflammasome is again required for
the secretion of IL-1b when macrophages are cultured
with CoCrMo alloy particles [36], suggesting that this
is a mechanism that should be investigated further in
prosthesis failures.
Therapeutic implications
With the increased knowledge of how crystals interact
with cells and their effects, treatments that target these
pathways have become feasible. Targeting the Syk path-
way by small molecule inhibitors has been tested for arth-
ritis [37], and would be one approach to modify the cellular
processes that are triggered by crystals, but no data have
been presented to date. Another approach is to inhibit the
inflammatory cytokines or mediators that are released
during inflammation. Targeting IL-1 is an obvious ap-
proach in gout, and this approach may also be useful in
patients who suffer from CPP- and BCP-induced arthritis.
To date, three anti-IL-1 agents have been evaluated in
gout, either in treatment of the acute attack or in the
prevention of an attack while initiating urate-lowering ther-
apy (Table 1). Overall, IL-1 inhibitors appear to be highly
effective in reducing pain and signs of inflammation, and
validate the concept that IL-1 is a key cytokine in gouty
inflammation. Patients who were given anakinra in open
studies were patients who had either failed to respond
adequately to treatments such as steroids, colchicine or
NSAIDs, or else had contraindications or intolerance to
TABLE 1 Studies evaluating IL-1 inhibitors in gout
Agent Study design References
Anakinra Open-label study in acute gout in 10 patients So et al. [38]
Open-label study in 15 patients Cho et al. [39]
Rilonacept RCT of rilonacept in 10 patients with chronic gouty arthritis Terkeltaub et al. [40]
RCT of rilonacept in prevention of gout flares on initiating allopurinol in 241
patients
Terkeltaub et al. [41]
Canakinumab RCT of canakinumab vs triamcinolone acetate in acute gout in 200 patients So et al. [42]
RCT of canakinumab vs colchicine in prevention of acute flares on initiating
allopurinol in 432 patients
Schlesinger et al. [43]
www.rheumatology.oxfordjournals.org 1157
Microcrystals as DAMPs in joint inflammation
these drugs. In the randomized controlled trials (RCTs) of
prevention of gout flares when initiating urate-lowering
therapy, both rilonacept and canakinumab markedly
reduced the incidence of flares when compared with
either placebo or colchicine, respectively.
Extrapolating from the in vitro and in vivo findings, one
would expect that other forms of acute crystal arthropa-
thies would respond to IL-1 inhibition as well. Two reports
of difficult cases of CPP responding to anakinra have
been published to date [44, 45], but no RCTs have been
performed so far. The situation with BCP-associated
arthropathies is unknown, as no studies have been re-
ported to date. However, in knee OA, a condition that is
frequently associated with Ca++ crystal deposition, a con-
trolled trial of anakinra, given as a single IA injection,
was not superior to placebo in terms of pain relief at
12 weeks after injection [46]. The lack of efficacy may
be due to the short half-life of the compound and the
single injection used. Interestingly, in a study of three
cases of erosive finger OA that did not respond to con-
ventional NSAIDs, the authors reported a positive effect
of anakinra given for more than 3 months on pain and
function [47].
Besides efficacy considerations, questions about safety
and cost as well as the most appropriate group of patients
who should receive this type of treatment have to be
raised. To date, short-term treatments with IL-1 antagon-
ists have not shown an adverse safety profile, but there
are justified concerns about immunosuppression and
risks of infections that longer-term studies will need to
address.
Summary
Over the last 5 years there have been major new insights
into the pathophysiology of microcrystal-induced dis-
eases, as well as our knowledge of how endogenous
and exogenous ‘danger signals’ lead to cell activation.
These include their interactions with the innate immune
system and cell signalling cascades to mediate inflamma-
tion, particularly the key role of IL-1b. These mechanisms
are likely to be relevant in diseases such as crystal-
induced arthritis, OA and atherosclerosis. Hopefully this
knowledge will lead to improved therapy in these
conditions.
Rheumatology key messages
. Microcrystals implicated in joint diseases elicit in-
flammatory and cellular responses from cells of the
innate immune system.
. IL-1b production by activation of the NLRP3 inflam-
masome is a common feature of microcrystal-
induced inflammation.
. Non-NLRP3 inflammasome pathways participate in
the generation of active IL-1b.
. Evidence is emerging that Syk kinase signalling
plays an important role in the cellular response to
microcrystals.
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Sea urchin spine-associated tenosynovitis—
recovery with hand therapy
A 55-year-old woman presented with a 6-month history of
stiffness and swollen right ring and middle fingers (Fig. 1)
following a diving trip to Kenya where she sustained
several sea urchin stings. Investigations including white
count, CRP, ESR, ENAs, ANAs and RF were negative.
Hand radiographs and US showed no bony abnormalities
or foreign bodies. MRI revealed florid tenosynovitis affect-
ing right flexor tendons limited to the ring and middle
fingers, without evidence of foreign bodies.
A diagnosis of sea urchin spine-associated tenosyno-
vitis was made based on history, clinical signs and symp-
toms. A plastic surgical opinion was sought; however,
surgical intervention was not required as no foreign
bodies were identified. She recovered with hand therapy
and analgaesia.
Sea urchin sting injuries are relatively common and
complications resulting from foreign body reaction or
sting toxins include persistent inflammation, arthritis,
granulomas and tenosynovitis. Antibiotics and anti-
inflammatories are reported to be unhelpful (although
early injection of steroids locally may suppress long-term
damage). Complete resolution of symptoms often requires
surgical removal of the spine or synovectomy [1].
However, there have been no reports of improvement
with hand therapy and analgaesia alone, which our patient
demonstrated.
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FIG. 1 Dorsal aspect of right hand showing swollen ring
finger.
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